Therefore, our studies are aimed at exploring the effect of SGLT2 inhibitor canagliflozin on HDL-c level and ANGPTL3 level in patients with T2DM and diabetic mice. This evidence concerns the gene ANGPTL3 and type 2 diabetes mellitus.